Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Belatacept as First Line Immunosuppression in De Novo Liver Transplant Recipients

NCT00555321 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT00555321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00555321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Belatacept as First Line Immunosuppression in De Novo Liver Transplant Recipients
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2008
Completion date
June 30, 2011
Enrollment
260 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

immunosuppression in solid organ transplant